초록 ▼

This invention describes a factor Xa analog which has a substitution of a minimum of one of the amino acid between Glu226 and Arg234 and possibly Ile235, relative to the amino acid numbering according to FIG. 1, a preparation containing the activated form of the factor X analog, and a method for the

This invention describes a factor Xa analog which has a substitution of a minimum of one of the amino acid between Glu226 and Arg234 and possibly Ile235, relative to the amino acid numbering according to FIG. 1, a preparation containing the activated form of the factor X analog, and a method for the production of these molecules.

대표청구항 ▼

1. A Factor X analog which contains one or more modifications in SEQ ID NO:2 selected from the group consisting of:a) Ile235 is Val or Ala; b) Thr233 is Ser or Asn; c) Leu232 is Phe, Arg or Ile; d) Asn231 is Asp, Lys, Thr, or Glu; e) Asn230 is Ser, Lys, Met, Thr, or Asp; f) Asp229 is Phe, Thr, Ser,

1. A Factor X analog which contains one or more modifications in SEQ ID NO:2 selected from the group consisting of:a) Ile235 is Val or Ala; b) Thr233 is Ser or Asn; c) Leu232 is Phe, Arg or Ile; d) Asn231 is Asp, Lys, Thr, or Glu; e) Asn230 is Ser, Lys, Met, Thr, or Asp; f) Asp229 is Phe, Thr, Ser, Pro, Leu, or Ile; g) Gly228 is Ser, Gln, Ile, Thr, Asn, or Pro; and h) Arg227 is Gln, Ser, His, Tyr, or Glu. 2. The Factor X analog of claim 1, wherein the amino acid sequence of residues 227-233 is Gln227-Ser228-Phe229-Asn230-Asp231-Phe232-Thr233 (SEQ ID NO:17).3. The Factor X analog of claim 1, wherein the amino acid sequence of residues 227-233 is Ser227-Gln228-Thr229-Ser230-Lys231-Leu232-Thr233 (SEQ ID NO:18).4. The Factor X analog of claim 1, wherein the modification forms a processing site for Factor XIa or a derivative thereof.5. A Factor X analog which(i) contains one or more modifications in SEQ ID NO:2 selected from the group consisting of: a) Ile235 is Val or Ala; b) Thr233 is Ser or Asn; c) Leu232 is Phe, Arg or Ile; d) Asn231 is Asp, Lys, Thr, or Glu; e) Asn230 is Ser, Lys, Met, Thr, or Asp; f) Asp229 is Phe, Thr, Ser, Pro, Leu, or Ile; g) Gly228 is Ser, Gln, Ile, Thr, Asn, or Pro; and h) Arg227 is Gln, Ser, His, Tyr, or Glu; and (ii) has a further modification occurring at Lys370 and/or within a segment extending from Arg 469 to Ser476 of SEQ ID NO:2. 6. The Factor X analog of claim 1, wherein said modification permits an in vivo activation of the Factor X analog into native Factor Xa or a Factor Xa analog.7. The Factor X analog of claim 1, wherein said modification permits an in vitro activation of the Factor X analog into native Factor Xa or a Factor Xa analog.8. The Factor X analog of claim 1 that contains an intact β-peptide.9. The Factor X analog of claim 1 which is in the form of a double-chain molecule.10. The Factor X analog of claim 1 having a shortened C-terminal region, wherein the C-terminal region corresponds to amino acid residues 476-487.11. A preparation comprising the Factor X analog of claim 1 or a precursor protein thereof.12. The preparation of claim 11, wherein the modification forms a cleavage site for Factor XIa or a derivative thereof.13. The preparation of claim 11, wherein the Factor X analog is a Factor Xα analog.14. The preparation of claim 11, wherein the Factor X analog has a shortened C-terminal amino acid sequence, wherein the C-terminal region corresponds to amino acid residues 476-487.15. The preparation of claim 11, wherein the Factor X analog is a double-chain molecule.16. The preparation of claim 11, wherein the Factor X analog is a single-chain Factor X analog in enzymatically inactive form that is at least 80% pure; andthe preparation does not contain inactive proteolytic intermediates of Factor X/Xa analog. 17. The preparation of claim 11, wherein the Factor X analog is a single-chain molecule.18. The preparation of claim 11, wherein the modification permits an in vivo activation of the Factor X analog into native Factor Xa or a Factor Xa analog.19. The preparation of claim 11, wherein the modification permits an in vitro activation of the Factor X analog into native Factor Xa or into a Factor Xa analog.20. The preparation of claim 11 that is formulated as a pharmaceutical preparation.21. A method for obtaining a preparation comprising an activated Factor X analog, the method comprising:(a) providing the Factor X analog of claim 1; and (b) activating the Factor X analog to obtain the activated Factor X analog. 22. The method of claim 21, further comprising formulating the preparation with a physiologically acceptable matrix.23. The method of claim 21, further comprising combining the preparation with a blood factor or an activated form of a blood factor as an additional component.24. The method of claim 23, wherein the additional component comprises at least one component with Factor VIII inhibitory bypass activity.25. The preparation of claim 11 that is formulated as a pharmaceutical compound and present as a multi-component preparation.26. A method for preparing a pharmaceutical composition, comprising formulating the preparation of claim 11 as pharmaceutical composition.27. The Factor X analog as set forth in claim 5, wherein the further modification is a substitution located at the β-peptide cleavage site located between Arg469 and Gly470 of SEQ ID NO:2.28. The Factor X analog as set forth in claim 5, wherein the further modification is selected from a mutation, a deletion and an insertion between amino acid positions Arg469 and Ser476 of SEQ ID NO:2.29. A Factor X analog which(i) contains one or more modifications in SEQ ID NO:2 selected from the group consisting of: a) Ile235 is Val or Ala; b) Thr233 is Ser or Asn; c) Leu232 is Phe, Arg or Ile; d) Asn231 is Asp, Lys, Thr, or Glu; e) Asn230 is Ser, Lys, Met, Thr, or Asp; f) Asp229 is Phe, Thr, Ser, Pro, Leu, or Ile; g) Gly228 is Ser, Gln, Ile, Thr, Asn, or Pro; and h) Arg227 is Gln, Ser, His, Tyr, Glu; and (ii) has a further modification which is a deletion of Factor X β-peptide (Gly470 to Lys488 of SEQ ID NO:2).